CN102711791A - 用于hiv疫苗组合物或作为诊断方法的hiv相关肽的组合或融合物 - Google Patents

用于hiv疫苗组合物或作为诊断方法的hiv相关肽的组合或融合物 Download PDF

Info

Publication number
CN102711791A
CN102711791A CN2010800392328A CN201080039232A CN102711791A CN 102711791 A CN102711791 A CN 102711791A CN 2010800392328 A CN2010800392328 A CN 2010800392328A CN 201080039232 A CN201080039232 A CN 201080039232A CN 102711791 A CN102711791 A CN 102711791A
Authority
CN
China
Prior art keywords
peptide
amino acid
domain
seq
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800392328A
Other languages
English (en)
Chinese (zh)
Inventor
马亚·索默费尔特·格伦沃尔
安格斯·达格利什
埃纳·滕内斯·兰格
延斯·奥勒夫·霍姆伯格
佩尔·本特松
比格尔·索伦森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionor AS
Original Assignee
Bionor AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionor AS filed Critical Bionor AS
Publication of CN102711791A publication Critical patent/CN102711791A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN2010800392328A 2009-07-03 2010-07-03 用于hiv疫苗组合物或作为诊断方法的hiv相关肽的组合或融合物 Pending CN102711791A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09164565.5 2009-07-03
EP09164565 2009-07-03
US22343609P 2009-07-07 2009-07-07
US61/223,436 2009-07-07
PCT/EP2010/059513 WO2011000962A2 (en) 2009-07-03 2010-07-03 Novel therapeutic and diagnostic means

Publications (1)

Publication Number Publication Date
CN102711791A true CN102711791A (zh) 2012-10-03

Family

ID=42752402

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800392328A Pending CN102711791A (zh) 2009-07-03 2010-07-03 用于hiv疫苗组合物或作为诊断方法的hiv相关肽的组合或融合物

Country Status (10)

Country Link
US (2) US9200065B2 (https=)
EP (1) EP2448593B1 (https=)
JP (1) JP5946766B2 (https=)
CN (1) CN102711791A (https=)
BR (1) BR112012000032A2 (https=)
CA (1) CA2767063A1 (https=)
EA (1) EA022788B1 (https=)
NZ (1) NZ597458A (https=)
WO (1) WO2011000962A2 (https=)
ZA (1) ZA201200370B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106282214A (zh) * 2016-08-03 2017-01-04 康众（北京）生物科技有限公司 一种快速获得纳米抗体的方法及其应用
CN107847591A (zh) * 2015-04-17 2018-03-27 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用
CN108593601A (zh) * 2018-04-11 2018-09-28 珠海国际旅行卫生保健中心 一种快速检测HIV-1的SPRi生物芯片制备方法及其应用
CN113143974A (zh) * 2021-03-03 2021-07-23 武汉科技大学 一种hiv感染致神经损伤动物模型的建立方法及其用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022788B1 (ru) 2009-07-03 2016-03-31 Бионор Иммуно Ас Новые терапевтические и диагностические средства
JP6294076B2 (ja) * 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 多量体ペプチド
FR2987836A1 (fr) * 2012-03-09 2013-09-13 Biomerieux Sa Peptides d'interference et procede de detection de microorganismes
AU2013273481B2 (en) 2012-06-06 2018-04-05 Bionor Immuno As HIV vaccine
IN2014KN02769A (https=) * 2012-06-06 2015-05-08 Bionor Immuno As
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
EP3099322A1 (en) 2014-01-27 2016-12-07 Bionor Immuno AS Method for the vaccination against hiv
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
RU2642258C1 (ru) * 2016-12-27 2018-01-24 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Рекомбинантный химерный полипептид-иммуноген nTBI, обладающий способностью индуцировать антитела, нейтрализующие вирус иммунодефицита человека 1 типа, и предназначенный для использования в качестве компонента вакцины против ВИЧ-1
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005196A1 (en) * 1990-09-25 1992-04-02 Hiver Limited Aids therapy and vaccine
CN1195702A (zh) * 1997-04-08 1998-10-14 军事医学科学院基础医学研究所 Hiv－1多表位重组膜抗原及其表达
WO2009042895A2 (en) * 2007-09-26 2009-04-02 Dana-Farber Cancer Institute, Inc. Reagents for inducing an immune response

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5298419A (en) * 1988-03-31 1994-03-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Human hybridomas and monoclonal antibodies which bind both gp41 and gp120 envelope proteins of human immunodeficiency virus
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5697151A (en) 1995-08-07 1997-12-16 General Electric Company Method for repairing partitions of a turbine diaphragm
AU724294B2 (en) 1997-01-22 2000-09-14 Eisai Inc. Microparticles for delivery of nucleic acid
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
SK4272001A3 (en) 1998-10-05 2003-02-04 Pharmexa As Methods for therapeutic vaccination
US6911527B1 (en) * 1999-01-11 2005-06-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services HIV related peptides
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
US20090203884A1 (en) * 2008-01-31 2009-08-13 Healthbanks Biotech Co., Ltd. Chimeric hiv fusion proteins as vaccines
EA022788B1 (ru) 2009-07-03 2016-03-31 Бионор Иммуно Ас Новые терапевтические и диагностические средства

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005196A1 (en) * 1990-09-25 1992-04-02 Hiver Limited Aids therapy and vaccine
CN1195702A (zh) * 1997-04-08 1998-10-14 军事医学科学院基础医学研究所 Hiv－1多表位重组膜抗原及其表达
WO2009042895A2 (en) * 2007-09-26 2009-04-02 Dana-Farber Cancer Institute, Inc. Reagents for inducing an immune response

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOHN R. MASCOLA,ET AL: "Protection of Macaques against Pathogenic Simin/Human Immunodediciency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies", 《JOURNAL OF VIROLOGY》 *
JOHN R. MASCOLA,ET AL: "Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies", 《NATURE MEDICINE》 *
杨为松主编: "《肾综合征出血热》", 28 February 1999 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847591A (zh) * 2015-04-17 2018-03-27 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用
CN106282214A (zh) * 2016-08-03 2017-01-04 康众（北京）生物科技有限公司 一种快速获得纳米抗体的方法及其应用
CN108593601A (zh) * 2018-04-11 2018-09-28 珠海国际旅行卫生保健中心 一种快速检测HIV-1的SPRi生物芯片制备方法及其应用
CN113143974A (zh) * 2021-03-03 2021-07-23 武汉科技大学 一种hiv感染致神经损伤动物模型的建立方法及其用途
CN113143974B (zh) * 2021-03-03 2023-06-06 武汉科技大学 一种hiv感染致神经损伤动物模型的建立方法及其用途

Also Published As

Publication number Publication date
US10251949B2 (en) 2019-04-09
US20120263720A1 (en) 2012-10-18
EA201270124A1 (ru) 2012-07-30
WO2011000962A2 (en) 2011-01-06
ZA201200370B (en) 2019-07-31
NZ597458A (en) 2014-01-31
BR112012000032A2 (pt) 2016-03-15
EP2448593B1 (en) 2020-11-25
JP2012531219A (ja) 2012-12-10
CA2767063A1 (en) 2011-01-06
US9200065B2 (en) 2015-12-01
WO2011000962A3 (en) 2011-03-31
EP2448593A2 (en) 2012-05-09
US20160144019A1 (en) 2016-05-26
AU2010267996A1 (en) 2012-02-02
EA022788B1 (ru) 2016-03-31
JP5946766B2 (ja) 2016-07-06
WO2011000962A9 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
CN102711791A (zh) 用于hiv疫苗组合物或作为诊断方法的hiv相关肽的组合或融合物
JP4216473B2 (ja) Ｈｉｖ感染および免疫疾患の予防および治療のペプチド組成物
US10561725B2 (en) Method of inducing the production of protective anti-HIV-1 antibodies
TWI445547B (zh) 登革熱病毒胜肽疫苗及其製備與使用方法
CN115785232A (zh) 用于预防或治疗冠状病毒感染的融合蛋白、Spike蛋白纳米颗粒及其应用
WO2022162012A2 (en) Antibodies broadly targeting coronaviruses and uses thereof
EP1879617A1 (en) Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2
KR20210122025A (ko) 신규 코로나바이러스 예방 및 치료용 백신 조성물
AU2010267996B2 (en) HIV related peptides combination or fusion for use in HIV vaccine composition or as diagnostic means
CN118320070A (zh) 一种冠状病毒多价疫苗及其应用
HK1174855A (en) Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
US10273292B2 (en) Non-HIV vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against HIV infection
CN118717961A (zh) 一种冠状病毒多价疫苗及其应用
CN119907804A (zh) 一种冠状病毒多价疫苗及其应用
Ichiyama et al. Epitope mapping of rat neutralizing monoclonal antibody against human immunodeficiency virus type-1 by a phage peptide library: comparison with ELISA using synthetic peptides
MXPA00011508A (en) Antigenic complex comprising immunostimulatory peptide, cd4, and chemokine receptor domain for hiv treatment and immune disorders
HK1036805B (en) Antigenic complex comprising immunostimulatory peptide, cd4, and chemokine receptor domain for hiv treatment and immune disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1174855

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1174855

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121003